Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Labeling for nicotine replacement products should direct physician consult, expert suggests.

This article was originally published in The Tan Sheet

Executive Summary

SMOKING CESSATION PRODUCT LABEL PHYSICIAN CONSULTATION DIRECTION necessary if the product is "not doing what it is supposed to do" as part of materials available to consumers, David Sachs, MD, Palo Alto Center for Pulmonary Disease Prevention, suggested at a June 9 meeting of FDA's Drug Abuse Advisory Committee in Bethesda, Md. Sachs addressed the committee during the open public hearing, saying nicotine replacement product labeling for consumers "must clearly...state, as is done for each and every other OTC category...when patients should see a physician because the medication is not doing what it is supposed to do."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel